Quality vs. Cost: Are Pharma Companies Missing a Trick to Reduce R&D Expenses?
"New research suggests tracking and analyzing 'costs of quality' in clinical development could significantly curb rising R&D spending."
For pharmaceutical companies, research and development (R&D) is the lifeblood, but the cost of bringing a new drug to market has become a major concern. R&D costs have been doubling every decade since the 1980s, creating a growing need to find efficiencies without compromising the quality and safety of new treatments. While much focus has been placed on streamlining processes, a recent study suggests an unexpected area holds considerable potential for cost reduction: quality management.
Quality management, often viewed as a compliance requirement, is increasingly being recognized as a competitive advantage. Pharma companies are beginning to focus on quality metrics, but a critical question remains: Are the costs associated with quality being tracked effectively within clinical development? A new study aimed to answer this question, surveying top global pharmaceutical companies to understand their current practices and identify potential areas for improvement.
The research highlights a significant gap: while tools and methodologies exist to track and analyze quality costs, their implementation within clinical development is not widespread. This article delves into the study's findings, exploring the potential benefits of tracking quality costs, the obstacles preventing its adoption, and the steps needed to unlock significant cost savings in pharmaceutical R&D.
The Pharmaceutical Productivity Gap
A 2024 review reports that R&D costs now exceed $3.5 billion per novel drug and describes a five-decade decline in pharmaceutical R&D efficiency. It analyzed financial data from the 200 largest pharmaceutical firms to assess whether recently reported signs of a turnaround represent a structural shift or a temporary reversal. The review frames the issue as a system-wide productivity challenge for the industry.
Balancing R&D Efficiency and Effectiveness
IQVIA describes pharmaceutical R&D productivity through two components: efficiency and effectiveness. Efficiency concerns the cost of turning inputs—including ideas, effort, and investment—into outputs such as approved new products; effectiveness concerns the quality of those outputs. This distinction shows why reducing expenditure alone does not capture R&D performance: quality must also be considered.
Rising Costs and Longer Timelines
A 2016 review reports that the costs associated with drug research and development, along with the time required to develop a new drug, have increased over the years. It also notes that drug-project success rates are part of the R&D efficiency challenge. The source presents these developments as a longstanding backdrop to efforts to improve pharmaceutical innovation.
The Untapped Potential: How Tracking Quality Costs Can Revolutionize Pharma R&D
The study revealed a surprising lack of emphasis on tracking and analyzing costs of quality within clinical development, despite readily available tools and proven benefits in other industries. This suggests that the pharmaceutical industry may be missing a significant opportunity to optimize its R&D spending. The core idea is that by investing in preventing quality failures and actively monitoring quality levels, companies can dramatically reduce overall costs.
- Better understand and control processes.
- Systematically and effectively measure costs of quality.
- Improve customer service activities, leading to increased customer satisfaction (critical for patient outcomes and adherence).
- Adopt a process-oriented business mentality that informs the cost accounting system.
R&D Productivity as an Industry Concern
A 2024 Nature review notes that pharmaceutical R&D productivity has long concerned industry analysts, citing discussion in the *Drug Information Journal* in 2000. The review frames productivity as a topic requiring more than a simple cost measure. This perspective is relevant to evaluating whether lower R&D expense can be achieved while maintaining the value and quality of development outcomes.
Process Development and Manufacturing Costs
A quantitative structured cost study estimated that process development and manufacturing costs per market success would account for 13–17% of the R&D budget from pre-clinical trials through approval. The study says its results can inform portfolio-management decisions and budget planning in biopharmaceutical development. The estimate identifies these activities as a defined share of development spending, rather than treating total R&D cost as a single undifferentiated figure.
Seizing the Opportunity: A Path Forward for Pharma
The study's findings underscore the need for a shift in mindset within the pharmaceutical industry. Quality management should be viewed not merely as a regulatory burden, but as a strategic tool for driving efficiency and reducing R&D costs. While challenges exist, the potential benefits are too significant to ignore.
Clinical Trial Costs Remain a Challenge
A PPD report published in July 2026 identifies rising clinical-trial costs as a challenge shaping pharmaceutical R&D. It says these costs are intensifying pressures faced by drug developers and describes organizations as adopting approaches to navigate current challenges. The source highlights trial expense as an area likely to remain central to efforts to manage R&D costs.
A Modernized R&D Model
Accenture argues that a modernized, holistic approach could help create a “future-fit” biopharma R&D organization. Its research suggests that this investment could bring discovery and development costs down from billions to millions and enable price reductions that broaden access. These are proposed potential outcomes of the transformation, rather than guaranteed savings.
Quality Improvement in an R&D Laboratory
A November 2024 study examined the combined use of 5S and Kaizen methods in a Greek pharmaceutical R&D laboratory. Using a single-case-study approach, it investigated their impact on quality-improvement processes and operational efficiency. The study therefore focuses on how workplace methods may affect both quality and efficiency in a specific laboratory setting.
Implementing a quality cost analysis model requires a collaborative effort, involving both clinical and finance departments. By working together, companies can develop systems for accurately tracking quality-related costs and identifying areas for improvement. This may involve:
The journey toward integrating quality cost analysis into clinical development won't happen overnight. However, by embracing a proactive approach to quality, pharmaceutical companies can unlock significant cost savings and gain a competitive edge in an increasingly challenging market. The key is to start tracking, start analyzing, and start improving.